Bristol Myers, Exelixis scored a kidney cancer combo win. But is there room for their duo on the market?

21st April 2020 Uncategorised 0

Bristol Myers Squibb and Exelixis have a potential kidney cancer contender on their hands with their Opdivo-Cabometyx combo. But the duo will have to meet a “high bar” to gain traction in the crowded field, one analyst says.

More: Bristol Myers, Exelixis scored a kidney cancer combo win. But is there room for their duo on the market?
Source: fierce